The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Central effects of GLP-1: new opportunities for treatments of neurodegenerative diseases
Open accessAbstract
The incretin hormone glucagon-like peptide 1 (GLP-1) has many effects in the body. It is best known for the ‘incretin effect’, facilitating insulin release from the pancreas under hyperglycaemic conditions. Building on this, GLP-1 mimetics have been developed as a treatment for type 2 diabetes. In the course of monitoring of patients, it has become apparent that GLP-1 mimetics have a range of other physiological effects in the body. In preclinical trials, a substantial body of evidence has been built that these mimetics have neuroprotective and anti-inflammatory effects. GLP-1 also has very similar growth-factor-like properties to insulin, which is presumably the underlying basis of the neuroprotective effects. In preclinical studies of Alzheimer's disease (AD), Parkinson's disease (PD), stroke and other neurodegenerative disorders, it has been shown that most GLP-1 mimetics cross the blood–brain barrier and show impressive neuroprotective effects in numerous studies. In animal models of AD, GLP-1 mimetics such as exendin-4, liraglutide and lixisenatide have shown protective effects in the CNS by reducing β-amyloid plaques, preventing loss of synapses and memory impairments, and reducing oxidative stress and the chronic inflammatory response in the brain. In animal models of PD, exendin-4 showed protection of dopaminergic neurons in the substantia nigra and prevention of dopamine loss in the basal ganglia while preserving motor control. These encouraging findings have spawned several clinical trials, some of which have shown encouraging initial results. Therefore, GLP-1 mimetics show great promise as a novel treatment for neurodegenerative conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Exercise builds brain health: key roles of growth factor cascades and inflammation
Cotman, C. W., Berchtold, N. C., & Christie, L.-A. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.06.011 · Cited by 2,268 · cited 1×
“These findings indicate that these drugs may be used as novel treatments for AD (Azzouz et al. 2004, Bradbury 2005, Cotman et al. 2007, Gregory-Evans et al. 2009, Holscher 2011). http://joe.endocrinology-journals.org DOI: 10.1530/JOE-13-0221 2014 Society for Endocrinology Printed in Great Britain”
BackgroundInfluentialTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“…that insulin signalling in the brain is desensitised in AD patients, and the brain tissue shows a very similar profile to that in diabetic people with respect to insulin signalling biomarkers of desensitisation in the periphery (Steen et al. 2005, Lester-Coll et al. 2006, Talbot et al. 2012).”
BackgroundInfluentialSteen, E., Terry, B. M., J. Rivera, E., Cannon, J. L., Neely, T. R., Tavares, R., Xu, X. J., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer's Disease · doi:10.3233/jad-2005-7107 · Cited by 1,703 · cited 2×
“…that insulin signalling in the brain is desensitised in AD patients, and the brain tissue shows a very similar profile to that in diabetic people with respect to insulin signalling biomarkers of desensitisation in the periphery (Steen et al. 2005, Lester-Coll et al. 2006, Talbot et al. 2012).”
BackgroundPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Increased Risk of Type 2 Diabetes in Alzheimer Disease
Janson, J., Laedtke, T., Parisi, J. E., O’Brien, P., Petersen, R. C., & Butler, P. C. (2004) · Diabetes · doi:10.2337/diabetes.53.2.474 · Cited by 950
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Intranasal insulin improves cognition and modulates β-amyloid in early AD
Reger, M. A., Watson, G. S., Green, P. S., Wilkinson, C. W., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Breitner, J. C. S., DeGroodt, W., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000265401.62434.36 · Cited by 830
Moloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationHyperinsulinemia and risk of Alzheimer disease
Luchsinger, J. A., Tang, M.-X., Shea, S., & Mayeux, R. (2004) · Neurology · doi:10.1212/01.wnl.0000140292.04932.87 · Cited by 683
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model
Azzouz, M., Ralph, G. S., Storkebaum, E., Walmsley, L. E., Mitrophanous, K. A., Kingsman, S. M., Carmeliet, P., & Mazarakis, N. D. (2004) · Nature · doi:10.1038/nature02544 · Cited by 590
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“In an in vivo study, exendin-4 protected dopaminergic neurons and rescued motor function in the 1-methyl-4phenyl-1,2,3,6-tetrahydropyridine lesion mouse model of PD (Li et al. 2009).”
BackgroundArakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 2×
“…exendin-4 can reduce monocyte adhesion to aortic endothelium in an inflammatory response in atherosclerosis and also prevents LPS-induced cytokine and chemokine release in both human and mouse monocytes (Arakawa et al. 2010) and an increase in microvascular permeability (Dozier et al. 2009).”
BackgroundCardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
Exenatide and the treatment of patients with Parkinson's disease
Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., Whitton, P., Wyse, R., Isaacs, T., Lees, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68295 · Cited by 529
Reger, M. A., Watson, G. S., Green, P. S., Baker, L. D., Cholerton, B., Fishel, M. A., Plymate, S. R., Cherrier, M. M., Schellenberg, G. D., Frey II, W. H., et al. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2008-13309 · Cited by 521
Hunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504 · cited 2×
“…studies in mouse models of AD and of diabetes or in wildtype mice that incretin analogues can increase or normalise neuronal progenitor cell proliferation in the CNS (During et al. 2003, Li et al. 2010, Porter et al. 2010a,b, Hamilton et al. 2011, McClean et al. 2011, Hunter & Holscher 2012).”
BackgroundSelf-citationInsulin and the insulin receptor in experimental models of learning and memory
Zhao, W.-Q., Chen, H., Quon, M. J., & Alkon, D. L. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.045 · Cited by 502
Craft, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362137 · Cited by 487 · cited 1×
“When administered by nasal application where it enters the brain more directly, insulin improved attention and memory formation (Craft 2007, Reger et al. 2008a,b).”
BackgroundInteractions of Glucagon-Like Peptide-1 (GLP-1) with the Blood-Brain Barrier
Kastin, A. J., Akerstrom, V., & Pan, W. (2002) · Journal of Molecular Neuroscience · doi:10.1385/jmn:18:1-2:07 · Cited by 480
Freiherr, J., Hallschmid, M., Frey, W. H., Brünner, Y. F., Chapman, C. D., Hölscher, C., Craft, S., De Felice, F. G., & Benedict, C. (2013) · CNS Drugs · doi:10.1007/s40263-013-0076-8 · Cited by 468
Self-citationIntracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer’s disease
Lester-Coll, N., Rivera, E. J., Soscia, S. J., Doiron, K., Wands, J. R., & de la Monte, S. M. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9102 · Cited by 467
Glucose metabolism and insulin receptor signal transduction in Alzheimer disease
Hoyer, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.049 · Cited by 434
Glucose tolerance status and risk of dementia in the community: The Hisayama Study
Ohara, T., Doi, Y., Ninomiya, T., Hirakawa, Y., Hata, J., Iwaki, T., Kanba, S., & Kiyohara, Y. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0435 · Cited by 420
Inflammation and Alzheimer’s disease
Lee, Y.-J., Han, S. B., Nam, S.-Y., Oh, K.-W., & Hong, J. T. (2010) · Archives of Pharmacal Research · doi:10.1007/s12272-010-1006-7 · Cited by 396
Protection and Reversal of Excitotoxic Neuronal Damage by Glucagon-Like Peptide-1 and Exendin-4
Perry, T., Haughey, N. J., Mattson, M. P., Egan, J. M., & Greig, N. H. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.037481 · Cited by 380 · cited 1×
“Exendin-4 has also been shown to reduce endogenous levels of b-amyloid in the mouse brain (Perry et al. 2003).”
BackgroundCommon pathological processes in Alzheimer disease and type 2 diabetes: A review
Li, L., & Hölscher, C. (2007) · Brain Research Reviews · doi:10.1016/j.brainresrev.2007.09.001 · Cited by 367
Self-citationEntry of exendin-4 into brain is rapid but may be limited at high doses
Kastin, A. J., & Akerstrom, V (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802206 · Cited by 355
Neurodegenerative disorders associated with diabetes mellitus
Ristow, M. (2004) · Journal of Molecular Medicine · doi:10.1007/s00109-004-0552-1 · Cited by 352
Perry, T., Lahiri, D. K., Sambamurti, K., Chen, D., Mattson, M. P., Egan, J. M., & Greig, N. H. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10611 · Cited by 347
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Li, Y., Duffy, K. B., Ottinger, M. A., Ray, B., Bailey, J. A., Holloway, H. W., Tweedie, D., Perry, T., Mattson, M. P., Kapogiannis, D., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1314 · Cited by 321
de la Monte, S. M., & Wands, J. R. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9209 · Cited by 316
Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease
Watson, G. S., & Craft, S. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.048 · Cited by 307
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Harkavyi, A., Abuirmeileh, A., Lever, R., Kingsbury, A. E., Biggs, C. S., & Whitton, P. S. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-19 · Cited by 289
Therapy insight, type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease
Haan, M. N. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0124 · Cited by 284
Parkinson's disease, insulin resistance and novel agents of neuroprotection
Aviles-Olmos, I., Limousin, P., Lees, A., & Foltynie, T. (2013) · Brain · doi:10.1093/brain/aws009 · Cited by 283
Carro, E., & Torres-Aleman, I. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.050 · Cited by 262
Kuipers, S. D., & Bramham, C. R. (2006) · PubMed · Cited by 254
(2011) · Reviews in the Neurosciences · doi:10.1515/revneuro · Cited by 239
Leptin Induces Insulin-like Signaling That Antagonizes cAMP Elevation by Glucagon in Hepatocytes
Zhao, A. Z., Shinohara, M. M., Huang, D., Shimizu, M., Eldar-Finkelman, H., Krebs, E. G., Beavo, J. A., & Bornfeldt, K. E. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11348 · Cited by 237
Grillo, C. A., Piroli, G. G., Hendry, R. M., & Reagan, L. P. (2009) · Brain Research · doi:10.1016/j.brainres.2009.08.005 · Cited by 233
The impact of comorbid disease and injuries on resource use and expenditures in parkinsonism
Pressley, J. C., Louis, E. D., Tang, M.-X., Cote, L., Cohen, P. D., Glied, S., & Mayeux, R. (2003) · Neurology · doi:10.1212/wnl.60.1.87 · Cited by 229
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 1×
“In the brain, GLP-1 receptors are expressed by neurons, in particular on pyramidal neurons in the hippocampus and neocortex, and Purkinje cells in the cerebellum (During et al. 2003, Perry et al. 2007, Hamilton & Holscher 2009).”
BackgroundSelf-citationInterleukin‐1β causes synaptic hyperexcitability in multiple sclerosis
Rossi, S., Furlan, R., De Chiara, V., Motta, C., Studer, V., Mori, F., Musella, A., Bergami, A., Muzio, L., Bernardi, G., et al. (2012) · Annals of Neurology · doi:10.1002/ana.22512 · Cited by 211
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210
Glucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207 · cited 2×
“Glia cells were not found to express this receptor but induced expression when activated in an inflammatory response (Iwai et al. 2006).”
BackgroundThe potential of anti-inflammatory drugs for the treatment of Alzheimer's disease
Aisen, P. S. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00133-3 · Cited by 203
Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., & Holst, J. J. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01357.x · Cited by 202
Teramoto, S., Miyamoto, N., Yatomi, K., Tanaka, Y., Oishi, H., Arai, H., Hattori, N., & Urabe, T. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2011.51 · Cited by 201
Stockhorst, U., de Fries, D., Steingrueber, H.-J., & Scherbaum, W. A. (2004) · Physiology & Behavior · doi:10.1016/j.physbeh.2004.07.022 · Cited by 192
Courrèges, J. ‐., Vilsbøll, T., Zdravkovic, M., Le‐Thi, T., Krarup, T., Schmitz, O., Verhoeven, R., Bugáñová, I., & Madsbad, S. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02484.x · Cited by 191
Perry, T., Holloway, H. W., Weerasuriya, A., Mouton, P. R., Duffy, K., Mattison, J. A., & Greig, N. H. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.09.028 · Cited by 182
Synaptic plasticity and learning and memory: LTP and beyond
Hölscher, C. (1999) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19991001)58:1<62::aid-jnr7>3.0.co;2-g · Cited by 174
Self-citationHölscher, C. (2011) · Biochemical Society Transactions · doi:10.1042/bst0390891 · Cited by 170
Self-citationGLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid
Gault, V. A., & Hölscher, C. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.03.025 · Cited by 168
Self-citationInsulin resistance impairs nigrostriatal dopamine function
Morris, J. K., Bomhoff, G. L., Gorres, B. K., Davis, V. A., Kim, J., Lee, P., Brooks, W. M., Gerhardt, G. A., Geiger, P. C., & Stanford, J. A. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.06.005 · Cited by 167
Benomar, Y., Naour, N., Aubourg, A., Bailleux, V., Gertler, A., Djiane, J., Guerre-Millo, M., & Taouis, M. (2006) · Endocrinology · doi:10.1210/en.2005-1464 · Cited by 162
Insulin-like growth factor-I, cognition and brain aging
van Dam, P. S., & Aleman, A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.047 · Cited by 160
Val(8)GLP-1 rescues synaptic plasticity and reduces dense core plaques in APP/PS1 mice
Gengler, S., McClean, P. L., McCurtin, R., Gault, V. A., & Hölscher, C. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.02.014 · Cited by 160
Self-citationMoroo, I., Yamada, T., Makino, H., Tooyama, I., McGeer, P. L., McGeer, E. G., & Hirayama, K. (1994) · Acta Neuropathologica · doi:10.1007/bf00313602 · Cited by 159
Porter, D. W., Kerr, B. D., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01259.x · Cited by 159
Self-citationLi, Y., Chigurupati, S., Holloway, H. W., Mughal, M. R., Tweedie, D., Bruestle, D. A., Mattson, M. P., Wang, Y., Harvey, B. K., Ray, B., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032008 · Cited by 135
NSAID and Antioxidant Prevention of Alzheimer's Disease: Lessons from In Vitro and Animal Models
COLE, G. M., MORIHARA, T., LIM, G. P., YANG, F., BEGUM, A., & FRAUTSCHY, S. A. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1332.005 · Cited by 129
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127
Ayasolla, K., Khan, M., Singh, A. K., & Singh, I. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.04.007 · Cited by 124
Lee, C. H., Yan, B., Yoo, K., Choi, J. H., Kwon, S., Her, S., Sohn, Y., Hwang, I. K., Cho, J. H., Kim, Y., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22596 · Cited by 121
Beneficial Effects of Exendin-4 on Experimental Polyneuropathy in Diabetic Mice
Himeno, T., Kamiya, H., Naruse, K., Harada, N., Ozaki, N., Seino, Y., Shibata, T., Kondo, M., Kato, J., Okawa, T., et al. (2011) · Diabetes · doi:10.2337/db10-1462 · Cited by 120
Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors
Holst, J. J. (2004) · Expert Opinion on Emerging Drugs · doi:10.1517/eoed.9.1.155.32952 · Cited by 116
Complex Genetics of Amyotrophic Lateral Sclerosis
Kunst, C. B. (2004) · The American Journal of Human Genetics · doi:10.1086/426001 · Cited by 113
Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus
Biessels, G. J. (2005) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.069583 · Cited by 103
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Bayliss, W. M., & Starling, E. H. (1902) · Proceedings of the Royal Society of London · doi:10.1098/rspl.1901.0119 · Cited by 101
Hölscher, C., & Li, L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.08.023 · Cited by 100
Self-citationWang, X. H., Li, L., Hölscher, C., Pan, Y. F., Chen, X. R., & Qi, J. S. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.08.028 · Cited by 99 · cited 1×
“…11/20/2021 06:11:06PM via Massachusetts Inst of Technology Jo u rn a l o f E n d o cr in o lo g y accumulates in the brains of AD patients, it was found that Val(8)GLP-1 prevented the blocking of synaptic plasticity in the brain and prevented the impairment of spatial learning (Wang et al. 2010).”
BackgroundSelf-citationPorter, D. W., Irwin, N., Flatt, P. R., Hölscher, C., & Gault, V. A. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.059 · Cited by 93
Self-citationEgefjord, L., Gejl, M., Møller, A., Brændgaard, H., Gottrup, H., Antropova, O., Møller, N., Poulsen, H. E., GJEDDE, A. H., Brock, B., et al. (2012) · PubMed · Cited by 91
Hölscher, C. (2005) · Reviews in the Neurosciences · doi:10.1515/revneuro.2005.16.3.181 · Cited by 86
Self-citationMeasures of striatal insulin resistance in a 6-hydroxydopamine model of Parkinson's disease
Morris, J. K., Zhang, H., Gupte, A. A., Bomhoff, G. L., Stanford, J. A., & Geiger, P. C. (2008) · Brain Research · doi:10.1016/j.brainres.2008.08.089 · Cited by 83
Aharoni, R., Vainshtein, A., Stock, A. D., Eilam, R., From, R., Shinder, V., & Arnon, R. (2011) · Journal of Autoimmunity · doi:10.1016/j.jaut.2011.06.003 · Cited by 82
Insulin and cognitive function in humans: experimental data and therapeutic considerations
Strachan, M. W. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331037 · Cited by 77
Biessels, G. J., Bravenboer, B., & Gispen, W. H. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.057 · Cited by 76
Perispinal etanercept: Potential as an Alzheimer therapeutic
Griffin, W. S. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-3 · Cited by 71
Knippenberg, S., Thau, N., Dengler, R., Brinker, T., & Petri, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036857 · Cited by 64
Neuroprotection and neurogeneration in MS and its animal model EAE effected by glatiramer acetate
Arnon, R., & Aharoni, R. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0272-3 · Cited by 64
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58
Gregory-Evans, K., Chang, F., Hodges, M., & Gregory, C. Y. (2009) · PubMed Central · Cited by 54
Insulin-like growth factor I and Alzheimer´s disease: therapeutic prospects?
Carro, E., & Torres‐Alemán, I. (2004) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.4.1.79 · Cited by 53
Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway
Wang, M., Huang, Y., Zhang, G.-P., Mao, L., Xia, Y., Mei, Y.-W., & Hu, B. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.025 · Cited by 51
Models of Alzheimer’s disease: cellular and molecular aspects
Hoyer, S. (1997) · Springer eBooks · doi:10.1007/978-3-7091-6844-8_2 · Cited by 48
McGovern, S. F. J., Hunter, K., & Hölscher, C. (2012) · Brain Research · doi:10.1016/j.brainres.2012.07.029 · Cited by 47
Self-citationLixisenatide: First Global Approval
Elkinson, S., & Keating, G. M. (2013) · Drugs · doi:10.1007/s40265-013-0033-3 · Cited by 37
Hope for AD with NGF gene-therapy trial
Bradbury, J. (2005) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70086-7 · Cited by 30
Okereke, O. I., Selkoe, D. J., Pollak, M., Stampfer, M. J., Hu, F. B., Hankinson, S. E., & Grodstein, F. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2089 · Cited by 25
Craft, S., Baker, L. D., Green, P. S., Minoshima, S., Cross, D. J., Montine, T. J., Watson, G. S., Fossen, B. V., Bonner, L. M., Wilkinson, C. W., et al. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.05.1998 · Cited by 10
Cited by
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
“Long term use of beinaglutide, a recombinant human GLP-1(7-36) acid, was demonstrated to reduce the body weight and improve steatosis (194).”
BackgroundInfluentialButterfield, D. A., Di Domenico, F., & Barone, E. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.06.010 · Cited by 402
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent
Mehdi, S. F., Pusapati, S., Anwar, M. S., Lohana, D., Kumar, P., Nandula, S. A., Nawaz, F. K., Tracey, K., Yang, H., LeRoith, D., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1148209 · Cited by 317
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Rowlands, J., Heng, J., Newsholme, P., & Carlessi, R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00672 · Cited by 302
“Fortunately, GLP-1 effects in the brain are reminiscent of its actions on pancreatic β-cells, signaling through GLP-1R to initiate anti-inflammatory, anti-apoptotic and pro-survival effects (250, 286, 287).”
BackgroundMicroglial phenotypes in Parkinson’s disease and animal models of the disease
Joers, V., Tansey, M. G., Mulas, G., & Carta, A. R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.04.006 · Cited by 285
Metadata
- Authors
- Hölscher, C.
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2013-09-02
- Volume
- 221
- Issue
- 1
- Pages
- T31-T41
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- OpenAlex
- W2148456968
- Cited by
- 288
- References
- 99
- FWCI
- 17.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.